Interrelationship Between Markers of Oxidative Stress, Inflammation and Hematological Parameters Among Preeclamptic Nigerian Women

Oloruntoba Ayodele Ekun  1
Nkeiruka Ogochukwu Ogidi  1
Rukayat Adetutu Lawal  1
Oluwumiwa Adeniran Ogumuyiwa  1
Mirian Chiamaka Umewune  1
Florence Oreitan Adefolaju  1,2
Mary Foluke Oshundun  1
Ayoola Islamiyat Oremosu  1,3

Corresponding Author: Oloruntoba Ayodele Ekun, e-mail: ayodele1619.oe@gmail.com
Source of support: Departmental sources

Background: Preeclampsia is a multifaceted pregnancy-related disorder affecting women and fetuses. A link between preeclampsia, oxidative stress, and inflammation has been suggested. This study evaluated the interrelationship between biomarkers of oxidative stress, inflammation, and hematological parameters among preeclamptic Nigerian women.

Material/Methods: A cross-sectional study was conducted among 49 preeclamptic and 50 normotensive healthy pregnant women. Blood samples were obtained after 20-week gestation in all participants. Levels of superoxide dismutase (SOD), catalase, glutathione (GSH), malondialdehyde (MDA), total protein, high-sensitivity C-reactive protein (hs-CRP), and cardiac-specific troponin I (cTnI) were determined by spectrophotometric and ELISA techniques. FBC, prothrombin time, and activated partial thromboplastin time were determined using an auto-analyzer, Quick's one-stage, and Proctor's and Rappaport's modification methods, respectively.

Results: The mean SOD (0.051±0.050 vs. 0.073±0.047, p 0.029), catalase (2.62±1.93 vs. 8.48±4.40, p<0.001), GSH (49.05±17.57 vs. 187.10±56.07 p<0.001), platelet (127.63±89.75 vs. 267.16±212.82, p<0.001) were lower in preeclampsia. MDA (7.16±5.00 vs. 2.91±2.66, p<0.001), cTnI (0.46±0.31 vs. 0.13±0.14 p<0.001), PT (19.36±4.06 vs. 13.45±1.97 p<0.001), APTT (45.53±2.92 vs. 37.49±4.99; p<0.001) were higher in preeclampsia. Negative associations between SOD and MDA (r –0.527 p<0.001), CAT and MDA (r –0.469, p 0.001) and positive associations between catalase and hs-CRP (r 0.844, p 0.029), RBC and HB (r 0.442, p 0.001), platelet, and SOD (r 0.353, p 0.013) were observed among preeclamptic volunteers.

Conclusions: Preeclampsia is associated with oxidative stress, derangement of hematological and coagulation homeostasis, as well as deleterious effects on the cardiovascular system.

MeSH Keywords: Blood Coagulation Tests • Oxidative Stress • Pre-Eclampsia • Troponin I

Abbreviations: PE – preeclampsia; SOD – superoxide dismutase; GSH – glutathione (reduced); CAT – catalase; MDA – malondialdehyde; PT – prothrombin time; APTT – activated partial thromboplastin; cTnI – cardiac troponin-I; hs-CRP – high-sensitivity C-reactive protein; LV – left ventricle

Full-text PDF: https://www.basic.medscimonit.com/abstract/index/idArt/910660

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Preeclampsia is a human pregnancy-specific disorder that adversely affects the mother and the fetus. It is a common condition of pregnancy, marked by the onset of hypertension and proteinuria [1]. It has been suggested that the pathogenesis of pre-eclampsia is complex, since it is thought to involve interactions between numerous genetic, immunologic, and environmental factors [2]. In fetuses and newborns, the most frequent complications of preeclampsia are reduced amniotic fluid, fetal distress, intrauterine growth restriction (10–25%), prematurity (15–67%), low birth weight, with possibility of future cardiovascular complications [3–5].

The incidence of preeclampsia is 3–10% of pregnancies [6,7], with a recent study suggesting 2–8% [8]. It has been reported that the incidence of preeclampsia in developing countries is 7 times higher than in developed countries [9]. The syndrome associated with preeclampsia is polymorphic and is characterized by generalized endothelial damage, which can result in organ system damage [10].

A previous study has hypothesized that preeclampsia results from a reduction in uteroplacental perfusion, which leads to uteroplacental ischemia [10]. In preeclampsia, placenta trophoblasts do not develop normally and are unable to invade the myometrium effectively [11]. The only intervention that effectively reverses the syndrome is delivery. A large portion of perinatal mortality is consequently due to iatrogenic prematurity. Up to 15% of preterm births are a result of preeclampsia [12]. The combination of hypertension and proteinuria markedly increases the risk of perinatal morbidity and mortality over that of hypertension alone [13]. It has been suggested that maternal endothelial cell dysfunction may be the key event resulting in the diverse clinical manifestations of preeclampsia [14]. Evidence has since accumulated to support a major role of the endothelium in preeclampsia [14,15]. The mechanisms involved in induction of endothelial cell dysfunction are poorly understood. Abnormal placentation is clearly involved in the genesis of both preeclampsia and fetal intrauterine growth restriction (IUGR) [16,17].

It has been proposed that product(s) of the fetal-placental unit enter the circulation and then initiate the maternal pathophysiological changes of preeclampsia [18]. However, there is increasing evidence that both fetoplacental and maternal factors interact in manifesting endothelial cell dysfunction and its clinical manifestations [15,19–21]. Other previous studies have also hypothesized that placental and maternal free radical reactions may promote a cycle of events that compromise the defensive functioning of the vascular endothelium in preeclampsia [14,22]. Thus, in preeclampsia, evidence of oxidative stress (a consequence of free radical generation) may be seen both in the maternal circulation and in the placenta, as the contents of placental micro-particles released into the maternal circulation during preeclampsia contributes to the elevated level of systemic oxidative stress [23–26]. It has also been reported that the pattern of left ventricular dysfunction and remodeling seen among preeclamptic individual is similar to that seen in early essential hypertension in non-pregnant women [27]. Thus, there is a need to evaluate some cardiac biomarkers among Nigerian preeclamptic patients in order to assess their status, since it has been suggested in a previous study that women with preeclampsia have a significantly higher risk of major adverse cardiovascular events (MACEs), especially myocardial infarction and stroke [28]. It has also been reported that preeclampsia can have deleterious effects on markers of hemostatic activities [29]. This study therefore evaluated the interrelationship between oxidative stress, inflammatory markers, cardiac specific troponin I, and hematological parameters among Nigerian preeclamptic women.

Material and Methods

Participants selection and study design

This was a cross-sectional study conducted on female preeclamptic patients and apparently healthy normotensive pregnant women attending Lagos University Teaching Hospital (LUTH), Ifako General Hospital, Isolo General Hospital, Lagos Island Maternity Hospital, and the Mother and Child Center Amuwo Odofin. A total of 99 volunteers participated in this study: 49 were preeclamptic volunteers while the remaining 50 were apparently healthy normotensive volunteers without urinary protein abnormality. The normotensive participants served as control. This study was conducted from July to November 2017. Blood samples were collected into dipotassium Ethylenediaminetetraacetic acid, trisodiumcitrate and serum separator tube (SST) gel vacutainer bottles in the morning from all consenting participants.

Ethical consideration

Approval was obtained from the Research and Ethics Committee College of Medicine of University of Lagos (CMUL) and the Lagos State Health Service Commission (HSC) prior to the commencement of the study. Informed consent was sought and obtained from all participants who volunteered to participate in this study.

Inclusion criteria

The following were included in this study: pregnant volunteers with gestational age greater than 20 weeks and preeclamptic women with no previous history of hypertension or proteinuria before gestational age of 20 weeks and above.
Exclusion criteria

The following were excluded from this study: pregnant women who were recently treated for Plasmodium infestation (malaria) and pregnant women with other medical conditions such as anemia, viral hepatitis, diabetes mellitus renal failure, tuberculosis, and auto-immune diseases.

Methodology

Malondialdehyde (MDA) level was determined using the method of Buege and Aust [30], while superoxide dismutase (SOD) level was determined based on the method described by Sun and Zigma [31]. Catalase level was determined according to the method of Sinha et al. [32]. Glutathione (GSH) level was estimated according to the method described by Sedlak and Lindsay [33]. Total protein level was determined using the Biuret method as described by Gonall et al. [34] and bovine serum albumin (BSA) was used as the standard. High-sensitivity C-reactive protein and cardiac-specific troponin I levels were determined by ELISA [35,36]. Full blood count was determined using a Mindray 5-part auto-analyzer. The prothrombin time test and activated partial thromboplastin test were performed using Quick’s one-stage method [37] and Proctor and Rapaport’s [38] Modification Method, respectively.

Data analysis

The data from the study were analyzed using IBM SPSS Statistics for Windows, version 21.0 (Armonk, NY). Quantitative data were expressed as mean, standard deviation, and standard error of the mean. The independent-samples t test was used to compare differences between groups. Pearson correlation coefficient was used to evaluate the degree of association. The level of significance for all the inferential statistics was set at p<0.05.

Results

Table 1 presents the mean SOD, CAT, MDA, and GSH values of preeclamptic volunteers and normotensive control group. The SOD, CAT, and GSH levels were 0.051 μmol/ml/min/mg protein vs. 0.073 μmol/ml/min/mg protein, 2.623 μmol/ml/min/mg protein vs. 8.483 μmol/ml/min/mg protein, and 49.05 μmol/ml vs. 187.10 μmol/ml for preeclamptic volunteers and normotensive control women, respectively.

Table 1. Comparative analysis of markers of oxidative stress in preeclampsia and control women.

| Variables                        | Preeclampsia Mean ±SD (n=49) | Control Mean ±SD (n=50) | t Value | p Value |
|----------------------------------|-------------------------------|-------------------------|---------|---------|
| SOD (μmol/ml/min/mg protein)     | 0.051±0.055                   | 0.073±0.047             | 2.211   | 0.029*  |
| CAT (μmol/ml/min/mg protein)     | 2.623±1.933                   | 8.483±4.427             | 8.503   | <0.001* |
| MDA (μmol/ml)                    | 7.158±5.005                   | 2.913±2.662             | –5.284  | <0.001* |
| GSH (μmol/ml)                    | 49.05±17.57                   | 187.10±56.07            | 16.459  | <0.001* |
| Cardiac-specific troponin-I (ng/ml) | 0.46±0.31                     | 0.13±0.14               | –6.635  | <0.001* |
| High-sensitivity CRP (µg/ml)     | 7.70±1.70                     | 5.46±0.95               | –1.240  | 0.218   |

* Significant probability (probability <0.05 is significant).

Table 2. Comparative analysis hematological and coagulation variables in preeclampsia and control women.

| Variables              | Preeclampsia Mean ±SD (n=49) | Control Mean ±SD (n=50) | t Value | p Value |
|------------------------|-------------------------------|-------------------------|---------|---------|
| WBC (×10^9/L)          | 7.35±5.54                     | 5.09±2.07               | –2.69   | 0.008*  |
| RBC (×10^12/L)         | 3.87±0.44                     | 3.73±0.45               | –1.47   | 0.144   |
| HGB (g/L)              | 115.92±11.33                  | 109.22±11.85            | –2.87   | 0.005*  |
| PLT (×10^9/L)          | 127.63±89.75                  | 267.16±212.82           | 4.24    | <0.001* |
| PT (s)                 | 19.36±4.06                    | 13.45±1.97              | –9.25   | <0.001* |
| APTT (s)               | 45.53±2.92                    | 37.49±4.99              | –9.74   | <0.001* |

* Significant probability (probability <0.05 is significant).
Table 3. Degree of association between markers of oxidative stress and inflammation measured.

| Variable correlation | Coefficient (r) | p Value |
|----------------------|----------------|---------|
| GSH-MDA              | −0.277         | 0.054   |
| SOD-MDA              | −0.527         | <0.001* |
| CAT-SOD              | 0.270          | 0.061   |
| CAT-MDA              | −0.469         | 0.001*  |
| CAT-hs-CRP           | 0.844          | 0.029*  |
| GSH-Troponin I       | 0.484          | 0.102   |
| SOD-hs-CRP           | −0.128         | 0.383   |

* Significant probability (probability <0.05 is significant).

Table 4. Pearson correlation studies on hematological and coagulation variables.

| Variables        | Correlation coefficient (r) | p Value |
|------------------|----------------------------|---------|
| WBC vs. RBC      | −0.075                     | 0.610   |
| WBC vs. HGB      | 0.001                      | 0.993   |
| RBC vs. HB       | 0.442                      | 0.001*  |
| PLT vs. PT       | −0.033                     | 0.823   |
| PLT vs. APTT      | 0.175                      | 0.229   |
| PT vs. RBC       | 0.282                      | 0.050   |

* Significant probability (probability <0.05 is significant).

In the present study, markers of oxidative stress were evaluated among preeclamptic volunteers. We observed a significantly higher MDA level (p<0.05) among preeclamptic women (Table 1), our observation is in agreement with previous studies by Madazli et al. [43], Chamy et al. [44], Patil et al. [45], Krishna et al. [46], Akiibinu et al. [47], and Ćebović et al. [48]. MDA is a marker of lipid peroxidation, suggesting that preeclamptic Nigerian women possibly experienced increased lipid peroxidation. Thus, an increase in MDA among preeclamptic women may be a key pathological factor importantly contributing to endothelial dysfunction and hypertension [48–50]. It has been suggested that lipid peroxidation causes oxidative stress in preeclampsia. However, a previous study has found that free radicals initiate lipid peroxidation by attacking polysaturated fatty acids in cell membranes [43]. Uncontrolled peroxidation of fatty acids and cholesterol alter membrane fluidity and permeability, as lipid peroxides are toxic compounds that damage endothelial cells, increase peripheral vasoconstriction, and increase thromboxane synthesis, as well as decreasing prostacyclin synthesis [51]. It has been suggested that a steady increase in blood lipid peroxide sets the stage for a self perpetuating chain-reaction processes to take place. Thus, endothelial contact with lipid peroxides would allow peroxidative damage of

Table 5. Pearson correlation studies on hematological, coagulation, and oxidative stress markers variables.

| Variables        | Correlation coefficient (r) | p Value |
|------------------|----------------------------|---------|
| PLT vs. SOD      | 0.353                      | 0.013*  |
| PLT vs. MDA      | −0.052                     | 0.724   |
| PT vs. SOD       | 0.156                      | 0.284   |
| PT vs. MDA       | −0.151                     | 0.299   |
| APTT-SOD         | 0.272                      | 0.059   |
| APTT-MDA         | 0.129                      | 0.375   |

* Significant probability (probability <0.05 is significant).

Discussion

Preeclampsia as a disorder of pregnancy has long affected humans [39]. It is a complex pregnancy disorder that occurs almost solely in humans [40]. The exact cause or etiology of preeclampsia is still unknown [39]. A previous study has suggested that preeclampsia is associated with oxidative stress [41], but another study has suggested that oxidative stress may be a cause rather than effect of preeclampsia [42].

Table 3 shows the degree of association among biochemical variables studied. There was an inverse association between superoxide dismutase (SOD) and malondialdehyde (MDA) (r=−0.527 p<0.001), as well as between catalase and malondialdehyde (MDA) (r=−0.469, p=0.001). Catalase correlated positively with high-sensitivity C-reactive protein (r=0.844 p=0.029). Table 4 shows correlation between hematological variables while Table 5 shows association between hematological variables and markers of oxidative stress. RBC correlated positively with Hb (r=0.442, p=0.001), while platelet correlated positively with SOD (r=0.353, p=0.013).
Thus, the abnormal LV remodeling as seen in some preeclamptic women suggests the possibility of subtle impairments of the vascular reactivity, as observed in this study, whereas hs-CRP did not show any significant increase among preeclamptic volunteers. As troponin I among preeclamptic volunteers was significantly higher among preeclamptic volunteers, it is possible that oxidative stress promotes platelet aggregation and endothelial damage.

Furthermore, in the present study we observed a significantly lower (p<0.05) reduced level of the studied antioxidants (SOD, CAT and GSH). Our observation agrees with some previous studies. A significant decrease (p<0.05) in the level of (SOD) enzymatic antioxidant has been suggested to be one of the hallmarks of preeclampsia, as this enzyme is one of the most important antioxidant defense mechanisms, and its lower activity has been used previously in predicting future development of preeclampsia as well as screening for low antioxidant status. Available data have shown that placenta from women with preeclampsia have reduced antioxidant capacity compared to normal placentas, and other studies have also shown that the levels of antioxidants in blood from women with preeclampsia are reduced. A possible explanation for this could be the deleterious effects of the free radicals released as an effect of preeclampsia.

Moreover, the mean hs-CRP value and cardiac-specific Troponin-I were determined among preeclamptic women. Troponin-I was significantly higher among preeclamptic volunteers, whereas hs-CRP did show any significant increase. An increase in troponin I among preeclamptic volunteers, as observed in this study, suggests the possibility of preeclampsia impacting deleterious effects on cardiac cells in the affected women. It appears that this observation supports a previous study, which reported that preeclampsia is associated with subtle impairments of the vascular reactivity, hemodynamic indices, and left ventricular (LV) functions. Thus, the abnormal LV remodeling as seen in some preeclamptic individuals may result in hypertrophy. Left ventricular involvement among preeclamptic individuals has been suggested to lead to cardiac ischemia, which may result in changes in some biomarkers of heart function.

An evaluation of prothrombin time test (PT) and activated partial thromboplastin time (APTT) among preeclamptic patients showed a significant increase (p<0.05) in these coagulation parameters when compared with the control group. Our finding regarding PT and APTT agree with a study by Ducloy-Bouthors, which reported that clotting disorders are associated with the severe early and complicated forms of preeclampsia. The changes in the mean PT and APTT might also be secondary to thrombocytopenia that resulted from exaggerated platelet activation and consumption, associated with preeclampsia. Thus, the significant increase in (PT) and (APTT) observed in our study corroborates the previous observation of Pinheiro et al. In preeclampsia, maternal inflammatory reaction and immunological activities are suggested to damage the coagulation-fibrinolytic system. In the present study, elevated prothrombin time test and activated partial thromboplastin time values among preeclamptic women suggest a deleterious effect of preeclampsia on hemostatic physiology. It has been shown that in preeclamptic pregnancies, the coagulation cascade is generally activated, suggesting that preeclampsia itself is associated with platelet activation and consumption, promotion of thrombin formation, and promotion of fibrin formation and destruction. In spite of these changes, in most cases of preeclampsia, the coagulation anomalies do not have major clinical significance. A balance between coagulation and anticoagulation has been shown to be vital to the regulation of utero-placenta circulation and organ perfusion in pregnancy. This balance is essential to prevent postpartum hemorrhage and its associated complications. This balance is probably disrupted in preeclampsia, which may expose such group of pregnant women to further complications.

Also, an association between markers of oxidative stress, hematological and coagulation profile as well as marker of inflammation were evaluated among preeclamptic volunteers. There was an inverse and significant (p<0.05) relationship between SOD and MDA, as well as between CAT and MDA (p<0.05) among preeclamptic women. These observations suggest the presence of oxidative stress in preeclampsia. There was a positive and significant association between hemoglobin (Hb) and red blood cell (RBC) count, whereas all other hematological and coagulation profiles did not show any significant association with one another. Platelet count correlated positively with SOD (p<0.05) among preeclamptic women. A significantly lower SOD value, as seen in this study, is suggestive of oxidative stress. The low SOD value in the present study was associated with low platelet count. This suggests that oxidative stress promotes platelet aggregation.
which invariably leads to platelet consumption with attendant thrombocytopenia [55] observed in some of the patients with preeclampsia. These observations show an imbalance between the biomarkers of oxidative stress markers among preeclamptic volunteers, suggesting that oxidative stress occurs among this group of individuals.

Conclusion

Our results show that preeclampsia is associated with oxidative stress, disturbance of hemostasis homeostasis as well as deleterious effects on cardiac cells.

References:

1. English FA, Kenny LC, McCarthy FP: Risk factors and effective management of preeclampsia. Integ Biomed Press Control, 2015; 8: 7–12
2. Roberts JM: Preeclampsia: What we know and what we do not know. Semin Perinatol, 2000; 24: 24–28
3. Sibai BM, Dekker G, Kupferminc M: Pre-clampsia. Lancet, 2005; 365: 785–99
4. Hladunewich M, Karumanchi SA, Lafayette R: Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol, 2007; 2(3): 543–49
5. Machado S, Neves M, Freitas L, Campos M: Diagnosis, pathophysiology and management of pre-eclampsia: A review. Port J Nephrol Hypert, 2013; 27(3): 153–61
6. Wallis AB, Saftlas AF, Hsia J, Atrash HK: Secular trends in the rates of pre-eclampsia, eclampsia, and gestational hypertension, United States, 1987–2004. Am J Hypertens, 2008; 21(5): 521–26
7. Duley L: The global impact of pre-eclampsia and eclampsia. Semin Perinatol, 2009; 33(3): 130–17
8. Jeyabalan A: Epidemiology of preeclampsia: Impact of obesity. Nutr Rev, 2013; 71(Suppl. 1): S18–25
9. Osungbade KO, Ige OK: Public health perspectives of preeclampsia in developing countries: implication for health system strengthening. J Pregnancy, 2011; 2011: 481095
10. Townsend R, O’Brien P, Khalil A: Current best practice in the management of hypertensive disorders in pregnancy. Integ Blood Press Control, 2016; 9: 79–94
11. Hladunewich M, Karumanchi SA, Lafayette R: Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol, 2007; 2: 543–49
12. Meis P, Goldenberg R, Mercer B: The preterm prediction study: Risk factors for indicated preterm births. Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am J Obstet Gynecol, 1998; 179: 562–67
13. Friedman E, Neff R: Pregnancy outcome as related to hypertension, edema, and proteinuria. In: Lindheimer M, Katz A, Zuspan F (eds.), Hypertension in Pregnancy. New York: John Wiley & Sons, 1999; 13
14. Roberts JM, Taylor RN, Musci TJ et al: Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol, 1989; 161: 1200–4
15. Taylor RN, Roberts JM: Endothelial cell dysfunction. In: Lindheimer MD, Roberts JM, Cunningham FG (eds.), Chesley’s Hypertensive Disorders in Pregnancy, 2nd ed. Stamford, CT: Appleton & Lange, 1998: 395–429
16. Redman CWO: Current topic: Preeclampsia and the placenta. Placenta, 1991; 12: 301–8
17. Cross JC: Trophoblast function in normal and preeclamptic pregnancy. Fetal Matern Med Rev, 1996; 8: 57–66
18. Roberts JM, Taylor RN, Musci RR et al: Preeclampsia: An endothelial cell disorder. Am J Obstet Gynecol, 1990; 163: 1365–66
19. Ness RB, Roberts JM: Heterogeneous causes constituting the single syndrome of preeclampsia: A hypothesis and its implications. Am J Obstet Gynecol, 1996; 175: 1365–70
20. Sattar N, Bedomir A, Berry C et al: Lipoprotein subfraction concentrations in preeclampsia: Pathogenic parallels to atherosclerosis. Obstet Gynecol, 1997; 89: 403–8
21. Sattar N, Gaw A, Packard CJ, Greer IA: Potential pathogenic roles of aberrant lipoprotein and fatty acid metabolism in preeclampsia. Br J Obstet Gynecol, 1997; 103: 614–20
22. Rodgers GM, Taylor RN, Roberts JM: Preeclampsia is associated with a serum factor cytotoxic to human endothelial cells. Am J Obstet Gynecol, 1988; 159: 908–14
23. Cronquist T, Salje K, Familari M et al: Syncytiotrophoblast vesicles show altered micro-RNA and haemoglobin content after ex vivo perfusion of placentas with haemoglobin to mimic preeclampsia. PLoS One, 2014; 9; e90220
24. Redman CW, Sargent IL: Circulating microparticles in normal pregnancy and pre-eclampsia. Placenta, 2008; 29: 573–77
25. Rudov A, Balduni W, Carloni S et al: Involvement of miRNAs in placental alterations mediated by oxidative stress. Oxid Med Cell Longev, 2014; 2014: 103068
26. Tannetta DS, Dragovic RA, Gardiner C et al: Characterisation of syncytiotrophoblast vesicles in normal pregnancy and pre-eclampsia: Expression of Flt-1 and endoglin. PLoS One, 2013; 8: e56754
27. Bijlonaars BH, Cikes M, Claus P, Sutherland GR: Velocity and deformation imaging for the assessment of myocardial dysfunction. Eur J Echocardiogr, 2009; 10: 216–26
28. Lin YS, Tang CH, Yang CY et al: Effect of pre-eclampsia-eclampsia on major cardiovascular events among peripartum women in Taiwan. Am J Cardiol, 2011; 107(2): 325–30
29. Irminger-Finger I, Jastraw N, Iiron O: Preeclampsia: A danger growing in disguise. Int J Biochem Cell Biol, 2008; 40: 1979–83
30. Buege JA, Aust SD: Microsomal lipid peroxidation. Methods Enzymol, 1978; 52: 302–10
31. Sun M, Zigma S: An improved spectrophotometric assay of superoxide dismutase based on epinephrine antioxidation. Anal Biochem, 1978; 90: 81–89
32. Sinha AK: Colorimetric assay of catalase. Anal Biochem, 1972; 47(2): 389–94
33. Seldak J, Lindsay RH: Estimation of total, protein-bound, and non-protein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem, 1968; 25: 1192–205
34. Gonall AG, Bardawill CJ, David MM: Determination of total protein. J Biol Chem, 1949; 175: 751–60
35. Engvall E, Perlmann P: Enzyme linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry, 1971; 8: 871–74
36. Sattar N, Perlmann P: Enzyme linked immunosorbent assay (ELISA). III. Quantitation of specific antibodies by enzyme-labelled anti-immunoglobulin in antigen coated tubes. J Immunol, 1972; 109: 129–35
37. Quick AJ: The prothrombin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol, 1961; 36: 212–19

Acknowledgment

The authors are grateful to the doctors and nurses of the Department of Obstetrics and Gynecology, Lagos University Teaching Hospital, and the various general hospitals under the Lagos Health Service Commission for their support during the time of this study.

Conflict of interest

None.

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0).

Acknowledged...
39. Bell MI: A historical overview of preeclampsia-eclampsia. J Obstet Gynaecol Neonatal Nurs, 2010; 39: 510–18
40. Lyall F, Belfort M: Pre-eclampsia, etiology and clinical practice. Cambridge University Press, Cambridge, USA, 2007
41. Sendar Z, Gür E, Colakoethullary M et al: Lipid and protein oxidation and antioxidant function in women with mild and severe preeclampsia. Arch Gynecol Obstet, 2003; 18: 69–25
42. Chappell LC, Seed PT, Briley AL et al: Effect of antioxidants on the occurrence of pre-eclampsia in women at increased risk: A randomised trial. Lancet, 1999; 354: 810–16
43. Madazli R, Benian A, Gumustas K: Lipid peroxidation and antioxidants in preeclampsia. Eur J Obstet Gynecol Reprod Biol, 1999; 85: 205–8
44. Chamy VM, Lepe J, Catalán A et al: Oxidative stress is closely related to clinical severity of pre-eclampsia. Biol Res, 2006; 39: 229–36
45. Patil SB, Kodliwadmath MV, Kodliwadmath SM: Role of lipid peroxidation and enzymatic antioxidants in pregnancy induced hypertension. Clin Exp Obstet Gynecol, 2007; 34: 239–41
46. Krishna MS, Venkataraman G: Status of lipid peroxidation, glutathione, ascorbic acid, vitamin E and antioxidant enzymes in patients with pregnancy induced hypertension. Indian J Physiol Pharmacol, 2007; 51: 284–88
47. Akilbusu MO, Kolawole TO, Ekun OA, Akilbusu SD: Metabolic dysfunction in Nigerian pre-eclampsics. Arch Gynaecol Obstet, 2013; 288(5): 1021–26
48. Čebović TN, Marić D, Nikolić A, Novakov-Mikić A: Antioxidant status in normotensive pregnancy with preeclampsia. Mol Cell Biochem, 2008; 313(1–2): 37–44
49. Kaur G, Mishra S, Sehgal A, Prasad R: Alterations in lipid peroxidation and antioxidant status in pregnancy with preeclampsia. Mol Cell Biochem, 2008; 313(1–2): 37–44
50. Kilstad EB, Nygård AE, Nygård J et al: Oxidative stress and changes related to placental-umbilical pathology in patients with preeclampsia, hypertensive pregnancy and preeclampsia and hypertension. Eur J Obstet Gynecol Reprod Biol, 2006; 117: 12–17
51. Alexia ID, Jera L: The role of oxidative stress in the etiology of preeclampsia. Rev Med Chir Soc Med Nat Lasi, 1996; 100: 131–35
52. Hubel CA, Roberts JM, Taylor RN et al: Lipid peroxidation in pregnancy: New perspectives on preeclampsia. Am J Obstet Gynecol, 1989; 161: 1025–34
53. Manasa K, Vani R: Influence of oxidative stress on stored platelets. Adv Haematol, 2016; 2016: 9410961
54. Han L, Liu X, Li H et al: Blood coagulation parameters and platelet indices: Changes in normal and preeclamptic pregnancies and predictive values for preeclampsia. PLoS One, 2014; 9(12): e114488
55. McCrae KR, Bussel JB, Mannucci PM et al: Platelets: an update on diagnosis and management of thrombocytopenic disorders. Hematology Am Soc Hematol Educ Program, 2001; 282–305
56. Mills JL, Desimonian R, Raymond E et al: Prostacyclin and thromboxane changes predicting clinical onset of preeclampsia: A multicenter prospective study. JAMA, 1999; 282: 356–62
57. Onisai M, Vladareanu A, Bumbea H et al: A study of the hematological picture and of platelet function in preeclampsia – report of a series of cases. Maedica, 2009; 4(4): 527–37
58. Wang Y, Walsh SW: Increased superoxide generation is associated with decreased superoxide dismutase activity and mRNA expression in placental trophoblast cells in preeclampsia. Placenta, 2001; 22: 206–12
59. Bernardi F, Constantino L, Machado R et al: Plasma nitric oxide, endothelin-1, arginase and superoxide dismutase in pre-eclamptic women. J Obstet Gynaecol Res, 2008; 34(6): 957–63
60. Dordević NZ, Babić GM, Marković SD et al: Oxidative stress and changes in antioxidative defense system in erythrocytes of preeclampsia in women. Reprod Toxicol, 2008; 25(2): 213–18
61. Rumiris D, Purwosunu Y, Wilowo N et al: Lower rate of preeclampsia after antioxidant supplementation in pregnant women with low antioxidant status. Hypertens Pregnancy, 2006; 25(3): 241–53
62. Walsh SW: Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Sem Reprod Endocrinol, 1998; 16: 93–104
63. Hubel CA: Oxidative stress in the pathogenesis of preeclampsia. Proc Soc Exp Biol Med, 1999; 222: 222–35
64. Raijmakers MTM, Steegers EAP, Peters WHM: Glutathione S-Transferases and thiol concentrations in embryonic and early fetal tissues, Hum Reprod, 2001; 16(11): 2445–50
65. Droge W: Free radicals in the physiological control of cell function. Physiol Rev, 2002; 82(1): 47–95
66. De Paco C, Kametas N, Rencore G et al: Maternal cardiac output between 11 and 13 weeks of gestation in the prediction of pre-eclampsia and small for gestational age. Obstet Gynecol, 2008; 111: 292–300
67. Papageorghiou AT, Prefumo F, Leslie K et al: Defective endovascular trophoblast invasion in the first trimester is associated with increased maternal serum ischaemia-modified albumin. Hum Reprod, 2008; 23: 803–6
68. Ducloy-Bouthors ES: Clotting disorders and preeclampsia. Ann Fr Anesth Reanim, 2010; 29(5): e121–34
69. Pinheiro MB, Gomes KB, Dusse LM: Fibrinolytic system in preeclampsia. Clin Chem Acta, 2013; 416: 67–71
70. Heilmann L, Rath W, Pollow K: Hemostatic abnormalities in patients with severe preeclampsia. Clin Appl Thromb Hemost, 2007; 13: 285–91
71. Towsley DM: Hematologic complications of pregnancy. Semin Hematol, 2010; 39: 510–18